Evidence map›Paper›PMID 31937792›Full record

ArticleScientific reports2020

Efficient tissue-type specific expression of target genes in a tetracycline-controlled manner from the ubiquitously active Eef1a1 locus.

Kazuhito Sakamoto, Patrick D Rädler, Barbara L Wehde, Aleata A Triplett, Hridaya Shrestha, Rosa-Maria Ferraiuolo, Foued Amari, Vincenzo Coppola, Apostolos Klinakis, Argiris Efstratiadis and 1 more

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.7field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 4 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 2 countries.

Kazuhito SakamotoEppley Institute for Research in Cancer and Allied Diseases, University of Nebraska Medical Center, 985950 Nebraska Medical Center, Omaha, NE, 68198-5950, USA.
Patrick D RädlerEppley Institute for Research in Cancer and Allied Diseases, University of Nebraska Medical Center, 985950 Nebraska Medical Center, Omaha, NE, 68198-5950, USA.
Barbara L WehdeEppley Institute for Research in Cancer and Allied Diseases, University of Nebraska Medical Center, 985950 Nebraska Medical Center, Omaha, NE, 68198-5950, USA.
Aleata A TriplettEppley Institute for Research in Cancer and Allied Diseases, University of Nebraska Medical Center, 985950 Nebraska Medical Center, Omaha, NE, 68198-5950, USA.
Hridaya ShresthaDepartment of Oncology, Wayne State University School of Medicine and Tumor Biology Program, Barbara Ann Karmanos Cancer Institute, 4100 John R, EL01TM, Detroit, MI, 48201, USA.
Rosa-Maria FerraiuoloDepartment of Oncology, Wayne State University School of Medicine and Tumor Biology Program, Barbara Ann Karmanos Cancer Institute, 4100 John R, EL01TM, Detroit, MI, 48201, USA.
Foued AmariGenetically Engineered Mouse Modeling Core, Comprehensive Cancer Center, Ohio State University, Columbus, Ohio, USA.ORCID http://orcid.org/0000-0003-4904-877X
Vincenzo CoppolaDepartment of Cancer Biology and Genetics, College of Medicine and Comprehensive Cancer Center, Ohio State University, Columbus, Ohio, USA.ORCID http://orcid.org/0000-0001-6163-1779
Apostolos KlinakisCenter of Basic Research, Biomedical Research Foundation of the Academy of Athens, 11527, Athens, Greece.
Argiris EfstratiadisCenter of Basic Research, Biomedical Research Foundation of the Academy of Athens, 11527, Athens, Greece.
Kay-Uwe WagnerDepartment of Oncology, Wayne State University School of Medicine and Tumor Biology Program, Barbara Ann Karmanos Cancer Institute, 4100 John R, EL01TM, Detroit, MI, 48201, USA. wagnerk@karmanos.org.
Nebraska Medical Center · USWayne State University · USBiomedical Research Foundation of the Academy of Athens · GRThe Ohio State University · US

Funding

Translational Therapeutics Research Program (TT)P30CA016058 · NCI · OHIO STATE UNIVERSITY · PI Tasleem J Padamsee · 1985 to 2026
$132.3M
Tumor Biology and Microenvironment (Program 1)P30CA022453 · NCI · WAYNE STATE UNIVERSITY · PI PAUL M STEMMER · 1985 to 2026
$68.4M
CHEMICAL CARCINOGENESIS &CANCER BIOLOGYT32CA009476 · NCI · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI Jennifer D. Black · 1988 to 2026
$6.2M
Growth-Regulatory Signaling Networks in Breast CancerR01CA117930 · NCI · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI WAGNER, KAY-UWE · 2006 to 2016
$2.5M
JAK1 Signaling in Pancreatic Cancer Initiation and ProgressionR01CA202917 · NCI · WAYNE STATE UNIVERSITY · PI WAGNER, KAY-UWE · 2017 to 2021
$1.6M
NCI NIH HHS P30 CA016058NCI NIH HHS P30 CA022453NCI NIH HHS R01 CA117930NCI NIH HHS R01 CA202917NCI NIH HHS T32 CA009476
6 · The paper itself

Abstract

Using an efficient gene targeting approach, we developed a novel mouse line that expresses the tetracycline-controlled transactivator (tTA) from the constitutively active Eef1a1 locus in a Cre recombinase-inducible manner. The temporally and spatially controlled expression of the EF1-LSL-tTA knockin and activation of tTA-driven responder transgenes was tested using four transgenic lines that express Cre under tissue-specific promoters of the pancreas, mammary gland and other secretory tissues, as well as an interferon-inducible promoter. In all models, the endogenous Eef1a1 promoter facilitated a cell-type-specific activation of target genes at high levels without exogenous enhancer elements. The applicability of the EF1-LSL-tTA strain for biological experiments was tested in two studies related to mammary gland development and tumorigenesis. First, we validated the crucial role of active STAT5 as a survival factor for functionally differentiated epithelial cells by expressing a hyperactive STAT5 mutant in the mammary gland during postlactational remodeling. In a second experiment, we assessed the ability of the EF1-tTA to initiate tumor formation through upregulation of mutant KRAS. The collective results show that the EF1-LSL-tTA knockin line is a versatile genetic tool that can be applied to constitutively express transgenes in specific cell types to examine their biological functions at defined developmental stages.

Indexed as

AnimalsAnti-Bacterial AgentsFemaleGene Expression RegulationGenes, ReporterIntegrasesMaleMiceMice, TransgenicPeptide Elongation Factor 1Promoter Regions, GeneticTetracyclineTissue DistributionTrans-ActivatorsTransgenesAnti-Bacterial AgentsCre recombinaseEef1a1 protein, mouseIntegrasesPeptide Elongation Factor 1TetracyclineTrans-Activators

Identifiers

PMID31937792
PMCPMC6959320
OpenAlexW2999774369

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.